Pharmaco- and toxicokinetics of selected exogenous and endogenous estrogens: A review of the data and identification of knowledge gaps
暂无分享,去创建一个
Michael Goodman | Judy S LaKind | Donald R Mattison | D. Mattison | J. LaKind | M. Goodman | N. Karyakina | Nataliya Karyakina
[1] Julie E Goodman,et al. Low-dose effects and nonmonotonic dose-responses of endocrine disrupting chemicals: has the case been made? , 2012, Regulatory toxicology and pharmacology : RTP.
[2] R. Dorfman,et al. Estrogen assays using the rat uterus. , 1954, Endocrinology.
[3] C. Laughton,et al. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study. , 1998, Environmental health perspectives.
[4] J. Fisher,et al. Exposure Conditions and Pharmacokinetic Principles: Interpreting Bisphenol A Absorption in the Canine Oral Cavity , 2013, Environmental health perspectives.
[5] Judy S LaKind,et al. Daily intake of bisphenol A and potential sources of exposure: 2005–2006 National Health and Nutrition Examination Survey , 2010, Journal of Exposure Science and Environmental Epidemiology.
[6] Kannan Krishnan,et al. Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment. , 2012, Advances in experimental medicine and biology.
[7] Hugh A Barton,et al. Computational Modeling of Serum‐Binding Proteins and Clearance in Extrapolations Across Life Stages and Species for Endocrine Active Compounds , 2004, Risk analysis : an official publication of the Society for Risk Analysis.
[8] J. Lampe,et al. Urinary Equol Excretion with a Soy Challenge: Influence of Habitual Diet , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[9] Jeffrey W Fisher,et al. Prediction and evaluation of route dependent dosimetry of BPA in rats at different life stages using a physiologically based pharmacokinetic model. , 2013, Toxicology and applied pharmacology.
[10] F. Stanczyk,et al. Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. , 2013, Contraception.
[11] Shuk-Mei Ho,et al. Chapel Hill bisphenol A expert panel consensus statement: integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure. , 2007, Reproductive toxicology.
[12] Ronald N Hines,et al. The ontogeny of drug metabolism enzymes and implications for adverse drug events. , 2008, Pharmacology & therapeutics.
[13] Wolfgang Völkel,et al. QUANTITATION OF BISPHENOL A AND BISPHENOL A GLUCURONIDE IN BIOLOGICAL SAMPLES BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY , 2005, Drug Metabolism and Disposition.
[14] Ronald P. Brown,et al. Distribution of bisphenol A into tissues of adult, neonatal, and fetal Sprague-Dawley rats. , 2011, Toxicology and applied pharmacology.
[15] H. Yokota,et al. Bisphenol A glucuronidation and absorption in rat intestine. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[16] F. Berrino,et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. , 2004, European journal of endocrinology.
[17] K. Setchell,et al. Method of defining equol-producer status and its frequency among vegetarians. , 2006, The Journal of nutrition.
[18] Justin Teeguarden,et al. Development of a physiologically based pharmacokinetic model for estradiol in rats and humans: a biologically motivated quantitative framework for evaluating responses to estradiol and other endocrine-active compounds. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.
[19] S Z Cagen,et al. The relative bioavailability and metabolism of bisphenol A in rats is dependent upon the route of administration. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.
[20] J. Bucher,et al. Consortium-Based Science: The NIEHS’s Multipronged, Collaborative Approach to Assessing the Health Effects of Bisphenol A , 2012, Environmental health perspectives.
[21] B. Bhavnani,et al. Pharmacokinetics of 17β-Dihydroequilin Sulfate in Normal Postmenopausal Women Under Steady State Conditions , 2002, Journal of the Society for Gynecologic Investigation.
[22] T. Adachi. [Female infertility]. , 2002, Nihon rinsho. Japanese journal of clinical medicine.
[23] Leon Speroff,et al. Clinical gynecologic endocrinology and infertility , 1983 .
[24] T. Lumley,et al. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. , 2014, JAMA internal medicine.
[25] R. Jackson,et al. Toxicokinetics and lack of uterotropic effect of orally administered S-equol. , 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[26] K. Setchell,et al. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. , 2002, The Journal of nutrition.
[27] F. Barile. Effects of Chemicals , 2007 .
[28] Masahiro Wada,et al. Development of a physiologically based pharmacokinetic model for bisphenol A in pregnant mice. , 2007, Toxicology and applied pharmacology.
[29] E. Component. Documentation, Codebook, and Frequencies , 2006 .
[30] W. Völkel,et al. Determination of free and total bisphenol A in urine of infants. , 2011, Environmental research.
[31] R. W. Kuhn,et al. The serum transport of steroid hormones. , 1982, Recent progress in hormone research.
[32] C. Bardin,et al. A study of estrogen metabolic clearance rates and transfer factors. , 1969, The Journal of clinical investigation.
[33] N. Coldham,et al. Pharmacokinetics of [14C]genistein in the rat: gender-related differences, potential mechanisms of biological action, and implications for human health. , 2000 .
[34] K Polkowski,et al. Biological properties of genistein. A review of in vitro and in vivo data. , 2000, Acta poloniae pharmaceutica.
[35] K. Setchell,et al. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. , 1998, The American journal of clinical nutrition.
[36] A. Calafat,et al. Potential External Contamination with Bisphenol A and Other Ubiquitous Organic Environmental Chemicals during Biomonitoring Analysis: An Elusive Laboratory Challenge , 2013, Environmental health perspectives.
[37] A. Franke,et al. Serum levels and metabolic clearance of the isoflavones genistein and daidzein in hemodialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.
[38] C. Laymon. A. study , 2018, Predication and Ontology.
[39] S. Marchitti,et al. Human and rat ABC transporter efflux of bisphenol a and bisphenol a glucuronide: interspecies comparison and implications for pharmacokinetic assessment. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[40] K. Setchell,et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. , 2001, The Journal of nutrition.
[41] G. Williamson,et al. Dietary intake and bioavailability of polyphenols. , 2000, The Journal of nutrition.
[42] K. Pang,et al. Why we need proper PBPK models to examine intestine and liver oral drug absorption. , 2012, Current drug metabolism.
[43] P. Desai,et al. Single-dose and steady-state pharmacokinetic studies of S-equol, a potent nonhormonal, estrogen receptor &bgr;-agonist being developed for the treatment of menopausal symptoms , 2010, Menopause.
[44] Donald P. McDonnell,et al. Hormone Therapy: Physiological Complexity Belies Therapeutic Simplicity , 2004, Science.
[45] H. Nelson,et al. Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendations , 2012, Annals of Internal Medicine.
[46] M. W. van den Heuvel,et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. , 2005, Contraception.
[47] Kuresh Youdim,et al. Application of PBPK modelling in drug discovery and development at Pfizer , 2012, Xenobiotica; the fate of foreign compounds in biological systems.
[48] B. Soria,et al. Low doses of the endocrine disruptor Bisphenol‐A and the native hormone 17β‐estradiol rapidly activate the transcription factor CREB , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[49] D. Naiman,et al. Bisphenol A (BPA) daily intakes in the United States: Estimates from the 2003–2004 NHANES urinary BPA data , 2008, Journal of Exposure Science and Environmental Epidemiology.
[50] V. Moyer. Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: U.S. Preventive Services Task Force Recommendation Statement , 2013, Annals of Internal Medicine.
[51] D. Mattison,et al. Sex Differences in Pharmacokinetics and Pharmacodynamics , 2009, Clinical pharmacokinetics.
[52] Stephen B. Hulley,et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy : Heart and Estrogen/Progestin Study fellow-up (HERS II) , 2002 .
[53] Gary Williamson,et al. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. , 2005, The American journal of clinical nutrition.
[54] I. Sarda,et al. Radioimmunoassay of plasma equilin and estrone in postmenopausal women after the administration of premarin. , 1981, The Journal of clinical endocrinology and metabolism.
[55] K. Setchell,et al. Equol: history, chemistry, and formation. , 2010, The Journal of nutrition.
[56] Wei Xu,et al. Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action. , 2011, Chemical research in toxicology.
[57] Jonathan E. Brown,et al. Urinary isoflavone kinetics: the effect of age, gender, food matrix and chemical composition , 2004, British Journal of Nutrition.
[58] M. Marino,et al. Susceptibility of estrogen receptor rapid responses to xenoestrogens: Physiological outcomes , 2012, Steroids.
[59] Laura N. Vandenberg,et al. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. , 2012, Endocrine reviews.
[60] J. Westendorf,et al. Comparison of an array of in vitro assays for the assessment of the estrogenic potential of natural and synthetic estrogens, phytoestrogens and xenoestrogens. , 2001, Toxicology.
[61] K. Setchell,et al. Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. , 2002, The American journal of clinical nutrition.
[62] Gary Williamson,et al. Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. , 2005, The American journal of clinical nutrition.
[63] M. Longnecker,et al. Misuse of blood serum to assess exposure to bisphenol A and phthalates , 2013, Breast Cancer Research.
[64] Stephanie Läer,et al. Physiologically Based Pharmacokinetic Modeling: Methodology, Applications, and Limitations with a Focus on Its Role in Pediatric Drug Development , 2011, Journal of biomedicine & biotechnology.
[65] A. Buckler,et al. Menopausal hormone therapy for the primary prevention of chronic conditions. , 2013, American family physician.
[66] J. Ross,et al. Dietary flavonoids: bioavailability, metabolic effects, and safety. , 2002, Annual review of nutrition.
[67] G. Risbridger,et al. The Dual, Opposing Roles of Estrogen in the Prostate , 2009, Annals of the New York Academy of Sciences.
[68] B. Olde,et al. G protein‐coupled oestrogen receptor 1 (GPER1)/GPR30: a new player in cardiovascular and metabolic oestrogenic signalling , 2011, British journal of pharmacology.
[69] J. Stockman,et al. Association of Urinary Bisphenol A Concentration With Medical Disorders and Laboratory Abnormalities in Adults , 2010 .
[70] Qasim Chaudhry,et al. Scientific Opinion on the hazard assessment of endocrine disruptors: Scientific criteria for identification of endocrine disruptors and appropriateness of existing test methods for assessing effects mediated by these substances on human health and the environment , 2013 .
[71] Sang Wook Hwang,et al. Assessment of Bisphenol a Exposure in Korean Pregnant Women by Physiologically Based Pharmacokinetic Modeling , 2010, Journal of toxicology and environmental health. Part A.
[72] M. Stern. Pharmacology of conjugated oestrogens. , 1982, Maturitas.
[74] David Melzer,et al. Association of Urinary Bisphenol A Concentration with Heart Disease: Evidence from NHANES 2003/06 , 2010, PloS one.
[76] J. Fisher,et al. Pharmacokinetics of bisphenol A in neonatal and adult rhesus monkeys. , 2010, Toxicology and applied pharmacology.
[77] R. Newbold,et al. Uterine adenocarcinoma in mice treated neonatally with genistein. , 2001, Cancer research.
[78] Kevin W. Gaido,et al. Bisphenol A interacts with the estrogen receptor α in a distinct manner from estradiol , 1998, Molecular and Cellular Endocrinology.
[79] L. Astheimer,et al. The Key Importance of Soy Isoflavone Bioavailability to Understanding Health Benefits , 2008, Critical reviews in food science and nutrition.
[80] R. Jackson,et al. Elucidation of the metabolic pathway of S-equol in rat, monkey and man. , 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[81] T. Toth,et al. Semen quality and sperm DNA damage in relation to urinary bisphenol A among men from an infertility clinic. , 2010, Reproductive toxicology.
[82] B. Larijani,et al. Association of urinary bisphenol a concentration with type-2 diabetes mellitus , 2014, Journal of Environmental Health Science and Engineering.
[83] Hermann Fromme,et al. Determination of free and total bisphenol A in human urine to assess daily uptake as a basis for a valid risk assessment. , 2008, Toxicology letters.
[84] E. Silbergeld,et al. Organizational and activational effects of estrogenic endocrine disrupting chemicals. , 2002, Cadernos de saude publica.
[85] Roger L. Black,et al. Goodman and Gilman's The Pharmacological Basis of Therapeutics , 1991 .
[86] Wolfgang Völkel,et al. Metabolism and kinetics of bisphenol a in humans at low doses following oral administration. , 2002, Chemical research in toxicology.
[87] A. Calafat,et al. Assessing the quantitative relationships between preschool children's exposures to bisphenol A by route and urinary biomonitoring. , 2011, Environmental science & technology.
[88] G. Röll,et al. A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers , 2000, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.
[89] K. Boehm. [The flavonoids. I]. , 1959, Arzneimittel-Forschung.
[90] C. Longcope,et al. The metabolism of estradiol; oral compared to intravenous administration. , 1985, Journal of steroid biochemistry.
[91] Jerry L. Campbell,et al. Evaluating Pharmacokinetic and Pharmacodynamic Interactions with Computational Models in Supporting Cumulative Risk Assessment , 2011, International journal of environmental research and public health.
[92] Shiew-Mei Huang,et al. PBPK as a tool in regulatory review. , 2012, Biopharmaceutics & drug disposition.
[93] J. Chuang,et al. Development of a method for the determination of bisphenol A at trace concentrations in human blood and urine and elucidation of factors influencing method accuracy and sensitivity. , 2010, Journal of analytical toxicology.
[94] G. Williamson,et al. Review of the Factors Affecting Bioavailability of Soy Isoflavones in Humans , 2007, Nutrition and cancer.
[95] U. Westphal. Steroid-Protein Interactions Revisited , 1986 .
[96] G. Williamson,et al. Nutrients and phytochemicals: from bioavailability to bioefficacy beyond antioxidants. , 2008, Current opinion in biotechnology.
[97] A. Eisenfeld,et al. Estradiol is less potent than ethinyl estradiol for in vivo translocation of the mammalian liver estrogen receptor to the nucleus. , 1982, Endocrinology.
[98] J. Filser,et al. Distribution and unspecific protein binding of the xenoestrogens bisphenol A and daidzein , 2002, Archives of Toxicology.
[99] J. Lampe. Is equol the key to the efficacy of soy foods? , 2009, The American journal of clinical nutrition.
[100] A. Breckenridge,et al. An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay. , 1979, Contraception.
[101] Céline M. Laffont,et al. Similarity of Bisphenol A Pharmacokinetics in Rhesus Monkeys and Mice: Relevance for Human Exposure , 2010, Environmental health perspectives.
[102] R. Williams,et al. Williams Textbook of endocrinology , 1985 .
[103] Potential role of the interaction between equine estrogens, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) in the prevention of coronary heart and neurodegenerative diseases in postmenopausal women , 2003, Lipids in Health and Disease.
[104] J. Corton,et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. , 1998, Endocrinology.
[105] K. Hirschhorn,et al. Advances in Human Genetics , 1982, Springer US.
[106] Susan R Woskie,et al. NTP-CERHR expert panel report on the reproductive and developmental toxicity of bisphenol A. , 2008, Birth defects research. Part B, Developmental and reproductive toxicology.
[107] K. Anderson,et al. Sex and long-term soy diets affect the metabolism and excretion of soy isoflavones in humans. , 1998, The American journal of clinical nutrition.
[108] B. Rohde,et al. Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women. , 2012, Contraception.
[109] R. Greenblatt,et al. The fate of a large bolus of exogenous estrogen administered to postmenopausal women. , 1980, Maturitas.
[110] K. Setchell,et al. The pharmacokinetic behavior of the soy isoflavone metabolite S-(-)equol and its diastereoisomer R-(+)equol in healthy adults determined by using stable-isotope-labeled tracers. , 2009, The American journal of clinical nutrition.
[111] P. Magee. Is equol production beneficial to health? , 2010, Proceedings of the Nutrition Society.
[112] S. Reif,et al. Pharmacokinetics of drospirenone and ethinylestradiol in Caucasian and Japanese women , 2012, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.
[113] K. Setchell,et al. Bioavailability, disposition, and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes. , 2003, The Journal of nutrition.
[114] P. Toutain,et al. Bisphenol A (BPA) pharmacokinetics with daily oral bolus or continuous exposure via silastic capsules in pregnant rhesus monkeys: Relevance for human exposures. , 2014, Reproductive toxicology.
[115] D. Archer,et al. Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch. , 2013, Contraception.
[116] P. Sarrel,et al. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. , 2013, American journal of public health.
[117] Justin G Teeguarden,et al. A systematic review of Bisphenol A "low dose" studies in the context of human exposure: a case for establishing standards for reporting "low-dose" effects of chemicals. , 2013, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[118] S. Salomone,et al. Isoflavones: estrogenic activity, biological effect and bioavailability , 2012, European Journal of Drug Metabolism and Pharmacokinetics.
[119] J. Ménard,et al. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen. , 2007, Contraception.
[120] Beom Soo Shin,et al. PHYSIOLOGICALLY BASED PHARMACOKINETICS OF BISPHENOL A , 2004, Journal of toxicology and environmental health. Part A.
[121] H. Adlercreutz,et al. Plasma concentrations of phyto-oestrogens in Japanese men , 1993, The Lancet.
[122] J. Fisher,et al. Pharmacokinetics of bisphenol A in serum and adipose tissue following intravenous administration to adult female CD-1 mice. , 2012, Toxicology letters.
[123] K. Setchell,et al. Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women. , 2003, The American journal of clinical nutrition.
[124] B. Arjmandi,et al. Soy and its isoflavones: the truth behind the science in breast cancer. , 2013, Anti-cancer agents in medicinal chemistry.
[125] Qi Sun,et al. Urinary isoflavone concentrations are inversely associated with cardiometabolic risk markers in pregnant U.S. women. , 2014, The Journal of nutrition.
[126] François Bouzom,et al. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs? , 2012, Biopharmaceutics & drug disposition.
[127] C. Diliberti,et al. A randomized, multiple-dose parallel study to compare the pharmacokinetic parameters of synthetic conjugated estrogens, A, administered as oral tablet or vaginal cream , 2011, Menopause.
[128] G. Williamson,et al. A critical review of the bioavailability of glucosinolates and related compounds. , 2004, Natural product reports.
[129] A. Calafat,et al. Quantification of urinary conjugates of bisphenol A, 2,5-dichlorophenol, and 2-hydroxy-4-methoxybenzophenone in humans by online solid phase extraction–high performance liquid chromatography–tandem mass spectrometry , 2005, Analytical and bioanalytical chemistry.
[130] A. Järvinen,et al. Absorption and bioavailability of oestradiol from a gel, a patch and a tablet. , 1999, Maturitas.
[131] J. Kuhnau. The flavonoids. A class of semi-essential food components: their role in human nutrition. , 1976 .
[132] Daniel A Beard,et al. Physiologically based pharmacokinetic tissue compartment model selection in drug development and risk assessment. , 2012, Journal of pharmaceutical sciences.
[133] H. Tran,et al. A Delayed Nonlinear PBPK Model for Genistein Dosimetry in Rats , 2007, Bulletin of mathematical biology.
[134] S. Yen,et al. Circulating estradiol, estrone and gonadotropin levels following the administration of orally active 17beta-estradiol in postmenopausal women. , 1975, The Journal of clinical endocrinology and metabolism.
[135] J. Reynolds. Martindale : the extra pharmacopoeia , 1972 .
[136] E. Vittinghoff,et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.
[137] A. Karim. The pharmacokinetics of Norpace. , 1975, Angiology.
[138] W. Jusko,et al. Differences in pharmacokinetics and comparative bioavailability between premarin® and estratab® in healthy postmenopausal women , 1994 .
[139] T. Hedner,et al. Inhibition of 17 beta-estradiol metabolism by grapefruit juice in ovariectomized women. , 1994, Maturitas.
[140] A. Breckenridge,et al. The pharmacokinetics of a large (3 mg) oral dose of ethynylestradiol in women. , 1980, Contraception.
[141] T. Patterson,et al. Concurrent determination of bisphenol A pharmacokinetics in maternal and fetal rhesus monkeys. , 2013, Toxicology and applied pharmacology.
[142] S. Korenman,et al. Reproductive hormone function: the perimenopausal period and beyond. , 1978, Clinics in endocrinology and metabolism.
[143] A. LaCroix,et al. Oral contraceptive use and bone density in adolescent and young adult women. , 2010, Contraception.
[144] P. Toutain,et al. Simultaneous quantification of bisphenol A and its glucuronide metabolite (BPA-G) in plasma and urine: applicability to toxicokinetic investigations. , 2011, Talanta.
[145] R. Dorfman,et al. ESTROGEN ASSAYS USING THE RAT UTERUS1 , 1954 .
[146] B. Bhavnani,et al. Pharmacokinetics and pharmacodynamics of a novel estrogen Δ8-estrone in postmenopausal women and men , 1998, The Journal of Steroid Biochemistry and Molecular Biology.
[147] G. Williamson,et al. Dietary flavonoid and isoflavone glycosides are hydrolysed by the lactase site of lactase phlorizin hydrolase , 2000, FEBS letters.
[148] U. Westphal. Steroid-Protein Interactions II , 1986, Monographs on Endocrinology.
[149] Deborah Grady,et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.
[150] W. Welshons,et al. The Effective Free Fraction of Estradiol and Xenoestrogens in Human Serum Measured by Whole Cell Uptake Assays: Physiology of Delivery Modifies Estrogenic Activity , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[151] G Williamson,et al. Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver β‐glucosidase activity , 1998, FEBS letters.
[152] K. Setchell,et al. Equol Is a Novel Anti-Androgen that Inhibits Prostate Growth and Hormone Feedback1 , 2004, Biology of reproduction.
[153] S. Barnes,et al. Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signaling pathways. , 1998, The American journal of clinical nutrition.
[154] K. Setchell,et al. Equol: pharmacokinetics and biological actions. , 2010, The Journal of nutrition.
[155] E. Hersh,et al. Antibiotics and oral contraceptives. , 2002, Dental clinics of North America.
[156] A. LaCroix,et al. Oral contraceptive use and bone density change in adolescent and young adult women: a prospective study of age, hormone dose, and discontinuation. , 2011, The Journal of clinical endocrinology and metabolism.
[157] A. McTiernan,et al. Relation of BMI and Physical Activity to Sex Hormones in Postmenopausal Women , 2006, Obesity.
[158] D. Archer. The importance of pharmacokinetic studies in drug development. , 2013, Contraception.
[159] M. Leider. Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .
[160] David C. Anderson,et al. SEX‐HORMONE‐BINDING GLOBULIN , 1974, Clinical endocrinology.
[161] Alfonso R. Gennaro,et al. Remington:the science and practice of pharmacy , 1995 .
[162] D. Feldman,et al. Bisphenol-A: an estrogenic substance is released from polycarbonate flasks during autoclaving. , 1993, Endocrinology.
[163] C. Diliberti,et al. Steady-state pharmacokinetics of an extended-regimen oral contraceptive with continuous estrogen. , 2011, Contraception.
[164] S. Whitehead,et al. Phytoestrogens and their low dose combinations inhibit mRNA expression and activity of aromatase in human granulosa-luteal cells , 2006, The Journal of Steroid Biochemistry and Molecular Biology.
[165] K. Setchell,et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. , 2005, The American journal of clinical nutrition.
[166] B. Bhavnani. Pharmacokinetics and Pharmacodynamics of Conjugated Equine Estrogens: Chemistry and Metabolism , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[167] G. Flatz,et al. Genetics of lactose digestion in humans. , 1987, Advances in human genetics.
[168] R. Farrant,et al. The identification of the weak oestrogen equol [7-hydroxy-3-(4'-hydroxyphenyl)chroman] in human urine. , 1982, The Biochemical journal.
[169] L. Herrinton,et al. Relationship between urine bisphenol-A level and declining male sexual function. , 2010, Journal of andrology.
[170] A. Cohen,et al. Pharmacokinetic differences between Caucasian and Japanese subjects after single and multiple doses of a potential combined oral contraceptive (Org 30659 and EE). , 2003, Contraception.
[171] F. Stanczyk,et al. Pharmacology of conjugated equine estrogens: Efficacy, safety and mechanism of action , 2014, The Journal of Steroid Biochemistry and Molecular Biology.
[172] J. Brooks,et al. Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation , 2009, The Prostate.
[173] A. Järvinen,et al. Effect of dose on the absorption of estradiol from a transdermal gel. , 2000, Maturitas.
[174] D. Archer,et al. Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. , 2013, Contraception.
[175] S. Lewis,et al. Lower serum oestrogen concentrations associated with faster intestinal transit. , 1997, British Journal of Cancer.
[176] J. Ménard,et al. Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. , 2007, The Journal of clinical endocrinology and metabolism.
[177] M. Martín,et al. Interactions between phytoestrogens and human sex steroid binding protein. , 1995, Life sciences.
[178] M. Amiji,et al. Comparative pharmacokinetics and tissue distribution analysis of systemically administered 17-β-estradiol and its metabolites in vivo delivered using a cationic nanoemulsion or a peptide-modified nanoemulsion system for targeting atherosclerosis. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[179] D. Mattison,et al. Sex Differences in Drug Disposition , 2011, Journal of biomedicine & biotechnology.
[180] D. N. Kirk,et al. Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. , 1984, The American journal of clinical nutrition.
[181] T. Zacharewski,et al. In Vitro and in Vivo Interactions of Bisphenol A and Its Metabolite, Bisphenol A Glucuronide, with Estrogen Receptors α and β , 2001 .
[182] J. Corton,et al. Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor β. , 1998, Endocrinology.
[183] B. Katzenellenbogen,et al. Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. , 2004, Bioorganic & medicinal chemistry.
[184] A. Breckenridge,et al. An investigation of the pharmacokinetics of ethynylestsadiol in women using badioimmunoassay , 1979 .
[185] Harvey J Clewell,et al. Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding, and uterine tissue dose metrics of bisphenol A: a physiologically based pharmacokinetic approach. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.
[186] N. Coldham,et al. Pharmacokinetics of [(14)C]Genistein in the rat: gender-related differences, potential mechanisms of biological action, and implications for human health. , 2000, Toxicology and applied pharmacology.
[187] B. Fauser,et al. The pharmacokinetics and pharmacodynamics of dehydroepiandrosterone during use of an ethinylestradiol- and drospirenone-containing oral contraceptive , 2013, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.
[188] P. Murphy,et al. Bioavailability of soybean isoflavones depends upon gut microflora in women. , 1995, The Journal of nutrition.
[189] H. Yokota,et al. Bisphenol a glucuronide, a major metabolite in rat bile after liver perfusion. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[190] C. Fang,et al. Equol-Producing Status, Isoflavone Intake, and Breast Density in a Sample of U.S. Chinese Women , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[191] Davide Viaggi,et al. JRC SCIENTIFIC AND POLICY REPORTS , 2014 .
[192] J. Fisher,et al. Comparison of lifestage-dependent internal dosimetry for bisphenol A , ethinyl estradiol , a reference estrogen , and endogenous estradiol to test an estrogenic mode of action in Sprague-Dawley rats , 2014 .
[193] W. Stigelman,et al. Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .
[194] H. Rosenthal,et al. Binding of estrone sulfate in human plasma. , 1972, The Journal of clinical endocrinology and metabolism.
[195] A. Meli,et al. Fate of ingested radiolabeled ethynylestradiol and its 3-cyclopentyl ether in patients with bile fistulas. , 1969, The Journal of clinical endocrinology and metabolism.
[196] T. Zacharewski,et al. In vitro and in vivo interactions of bisphenol A and its metabolite, bisphenol A glucuronide, with estrogen receptors alpha and beta. , 2001, Chemical research in toxicology.
[197] R. Boyd,et al. The Effect of Food on the Bioavailability of Norethindrone and Ethinyl Estradiol from Norethindrone Acetate/Ethinyl Estradiol Tablets Intended for Continuous Hormone Replacement Therapy , 2003, Journal of clinical pharmacology.
[198] D. Mattison,et al. Bisphenol A and indicators of obesity, glucose metabolism/type 2 diabetes and cardiovascular disease: A systematic review of epidemiologic research , 2014, Critical reviews in toxicology.
[199] Chunyang Liao,et al. Widespread occurrence of bisphenol A in paper and paper products: implications for human exposure. , 2011, Environmental science & technology.
[200] S. Borghoff,et al. Physiologically‐Based Pharmacokinetic Modeling of Genistein in Rats, Part I: Model Development , 2006, Risk analysis : an official publication of the Society for Risk Analysis.
[201] M. Luján,et al. Comparative pharmacokinetics and pharmacodynamics after subcutaneous and intramuscular administration of medroxyprogesterone acetate (25 mg) and estradiol cypionate (5 mg). , 2011, Contraception.
[202] W. Pardridge,et al. Transport of protein-bound steroid hormones into liver in vivo. , 1979, The American journal of physiology.
[203] C. Watson,et al. Xenoestrogens at Picomolar to Nanomolar Concentrations Trigger Membrane Estrogen Receptor-α–Mediated Ca2+ Fluxes and Prolactin Release in GH3/B6 Pituitary Tumor Cells , 2005, Environmental health perspectives.
[204] J. Goldzieher. Pharmacology of contraceptive steroids: a brief review. , 1989, American journal of obstetrics and gynecology.
[205] C. Longcope,et al. Metabolic clearance rates and interconversions of estrone and 17beta-estradiol in normal males and females. , 1968, The Journal of clinical investigation.
[206] Chung-Hsiu Wu,et al. Free and Protein-Bound Plasma Estradiol-17β During the Menstrual Cycle , 1976 .
[207] Sean M Hays,et al. Biomonitoring Equivalents for bisphenol A (BPA). , 2010, Regulatory toxicology and pharmacology : RTP.
[208] C. Willhite,et al. Derivation of a Bisphenol a Oral Reference Dose (RfD) and Drinking-Water Equivalent Concentration , 2008, Journal of toxicology and environmental health. Part B, Critical reviews.
[209] David B. Troy. Remington : the science and practice of pharmacy , 2006 .
[210] S. Deitcher,et al. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. , 2004, Archives of internal medicine.
[211] B. Bhavnani,et al. Metabolic clearance rate of equilin sulfate and its conversion to plasma equilin, conjugated and unconjugated equilenin, 17 beta-dihydroequilin, and 17 beta-dihydroequilenin in normal postmenopausal women and men under steady state conditions. , 1993, The Journal of clinical endocrinology and metabolism.
[212] Hiroaki Numata,et al. Disposition of a low dose of bisphenol a in male and female cynomolgus monkeys. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.
[213] A. Gompel,et al. Comparative activity of pulsed or continuous estradiol exposure on gene expression and proliferation of normal and tumoral human breast cells. , 2002, Journal of molecular endocrinology.
[214] H. Adlercreutz,et al. Studies on the role of intestinal bacteria in metabolism of synthetic and natural steroid hormones. , 1985, Journal of steroid biochemistry.
[215] Xiaoyun Ye,et al. Measuring environmental phenols and chlorinated organic chemicals in breast milk using automated on-line column-switching-high performance liquid chromatography-isotope dilution tandem mass spectrometry. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[216] Amin Rostami-Hodjegan,et al. Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensus. , 2012, Current drug metabolism.
[217] C. Mendel,et al. The free hormone hypothesis. Distinction from the free hormone transport hypothesis. , 1992, Journal of andrology.
[218] B. Rubin,et al. Bisphenol A: An endocrine disruptor with widespread exposure and multiple effects , 2011, The Journal of Steroid Biochemistry and Molecular Biology.
[219] C H Wu,et al. Free and protein-bound plasma estradiol-17 beta during the menstrual cycle. , 1976, The Journal of clinical endocrinology and metabolism.
[220] D. Naiman,et al. Comparing United States and Canadian population exposures from National Biomonitoring Surveys: Bisphenol A intake as a case study , 2012, Journal of Exposure Science and Environmental Epidemiology.
[221] S Hulley,et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.
[222] Jeffrey W Fisher,et al. Pharmacokinetic modeling: prediction and evaluation of route dependent dosimetry of bisphenol A in monkeys with extrapolation to humans. , 2011, Toxicology and applied pharmacology.
[223] D. Back,et al. Interindividual variation in the metabolism of ethynylestradiol. , 1989, Pharmacology & therapeutics.
[224] N. Benda,et al. Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone. , 2008, Contraception.
[225] J. Goldzieher,et al. Pharmacokinetics of three bioequivalent norethindrone/mestranol-50ug and three norethindrone/ethinyl estradiol-35ug oc formulations: Are “low-dose” pills really lower? , 1989 .
[226] W. Verstraete,et al. Isolation and characterisation of an equol-producing mixed microbial culture from a human faecal sample and its activity under gastrointestinal conditions , 2004, Archives of Microbiology.
[227] J. Sumpter,et al. Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ERbeta. , 2000, The Journal of biological chemistry.
[228] Susan Budavari,et al. The Merck index , 1998 .
[229] D. Back,et al. Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration. , 1987, Contraception.
[230] J. Hengstler,et al. Critical evaluation of key evidence on the human health hazards of exposure to bisphenol A , 2011, Critical reviews in toxicology.
[231] B. Bhavnani,et al. Pharmacokinetics of equilin and equilin sulfate in normal postmenopausal women and men. , 1983, The Journal of clinical endocrinology and metabolism.
[232] A. Calafat,et al. Reconstruction of bisphenol A intake using a simple pharmacokinetic model , 2013, Journal of Exposure Science and Environmental Epidemiology.
[233] C. Verhoeven,et al. Effects on bone mineral density of a monophasic combined oral contraceptive containing nomegestrol acetate/17β‐estradiol in comparison to levonorgestrel/ethinylestradiol , 2012, Acta obstetricia et gynecologica Scandinavica.
[234] M. Meydani,et al. Bioavailability of soybean isoflavones from aglycone and glucoside forms in American women. , 2003, The American journal of clinical nutrition.
[235] Peiyu Wang,et al. Prevalence of the Equol-Producer Phenotype and Its Relationship with Dietary Isoflavone and Serum Lipids in Healthy Chinese Adults , 2010, Journal of epidemiology.
[236] P. Murphy,et al. Neither background diet nor type of soy food affects short-term isoflavone bioavailability in women. , 2000, The Journal of nutrition.
[237] D. Archer,et al. Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. , 2012, Contraception.
[238] N. Miyanaga,et al. Isoflavone supplements stimulated the production of serum equol and decreased the serum dihydrotestosterone levels in healthy male volunteers , 2009, Prostate Cancer and Prostatic Diseases.
[239] R. Miksicek. Estrogenic Flavonoids: Structural Requirements for Biological Activity , 1995, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[240] J. Gustafsson,et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. , 1997, Endocrinology.
[241] Zbigniew Dauter,et al. Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.
[242] D. Rice,et al. Does Rapid Metabolism Ensure Negligible Risk from Bisphenol A? , 2009, Environmental health perspectives.
[243] Ulrich Westphal,et al. Steroid-Protein Interactions , 1971, Monographs on Endocrinology.
[244] A. Malovannaya,et al. Minireview: nuclear receptor and coregulator proteomics--2012 and beyond. , 2012, Molecular endocrinology.
[245] H Kuhl,et al. Pharmacology of estrogens and progestogens: influence of different routes of administration , 2005, Climacteric : the journal of the International Menopause Society.
[246] J. Dwyer,et al. Estrogen metabolism and excretion in Oriental and Caucasian women. , 1994, Journal of the National Cancer Institute.
[247] W. Mazur,et al. Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako). , 1998, The Journal of nutrition.
[248] Effects of Estrogen Replacement on the Progression of Coronary-Artery Atherosclerosis , 2001 .
[249] I. Hayasaka,et al. Toxicokinetics of bisphenol A in rats, monkeys and chimpanzees by the LC-MS/MS method. , 2006, Toxicology.
[250] M. Shelby. NTP-CERHR monograph on the potential human reproductive and developmental effects of bisphenol A. , 2008, NTP CERHR MON.
[251] M. Mendelsohn,et al. Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: Insights from basic science and clinical studies. , 2006, Endocrine reviews.
[252] S. Shoaf,et al. The pharmacokinetics of S-(-)equol administered as SE5-OH tablets to healthy postmenopausal women. , 2009, The Journal of nutrition.
[253] D. Naiman,et al. Correction: Use of NHANES Data to Link Chemical Exposures to Chronic Diseases: A Cautionary Tale , 2013, PLoS ONE.
[254] J. Fisher,et al. Pharmacokinetics of bisphenol A in neonatal and adult CD-1 mice: inter-species comparisons with Sprague-Dawley rats and rhesus monkeys. , 2011, Toxicology letters.
[255] Margaret Warner,et al. Estrogen receptors: how do they signal and what are their targets. , 2007, Physiological reviews.
[256] H. Adlercreutz,et al. Effect of oxytetracycline administration on intestinal metabolism of oestrogens and on plasma sex hormones in healthy men. , 1987, Gut.
[257] R. Pasquali,et al. Determinants of sex hormone-binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status. Virgilio-Menopause-Health Group. , 1997, Metabolism: clinical and experimental.
[258] K. Setchell,et al. Exposure of infants to phyto-oestrogens from soy-based infant formula , 1997, The Lancet.
[259] M Carlquist,et al. Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist , 1999, The EMBO journal.
[260] J. Fisher,et al. Pharmacokinetics of bisphenol A in neonatal and adult Sprague-Dawley rats. , 2010, Toxicology and applied pharmacology.
[261] C. Gerlinger,et al. A pharmacokinetic study with a low-dose oral contraceptive containing 20 μg ethinylestradiol plus 100 μg levonorgestrel , 2002 .
[262] Frederick S vom Saal,et al. Large effects from small exposures. III. Endocrine mechanisms mediating effects of bisphenol A at levels of human exposure. , 2006, Endocrinology.
[263] K. P. Phillips,et al. Assessing and Managing Risks Arising from Exposure to Endocrine-Active Chemicals , 2008, Journal of toxicology and environmental health. Part B, Critical reviews.
[264] M. Waring,et al. The Variable Metabolic Response to Dietary Isoflavones in Humans , 1995, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[265] J. Fisher,et al. Comparison of life-stage-dependent internal dosimetry for bisphenol A, ethinyl estradiol, a reference estrogen, and endogenous estradiol to test an estrogenic mode of action in Sprague Dawley rats. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.
[266] X. Lu,et al. Structure activity relationships and differential interactions and functional activity of various equine estrogens mediated via estrogen receptors (ERs) ERalpha and ERbeta. , 2008, Endocrinology.
[267] C. Gerlinger,et al. Population pharmacokinetic/pharmacodynamic evaluation of low-dose drospirenone with 17&bgr;-estradiol in postmenopausal women with moderate to severe vasomotor symptoms , 2014, Menopause.
[268] L. Mattsson,et al. Bioavailability of norethisterone acetate alone and in combination with estradiol administered in single or multiple oral doses to postmenopausal women. , 1999, Maturitas.
[269] B. Y. Tang,et al. Effect of equol on oestrogen receptors and on synthesis of DNA and protein in the immature rat uterus. , 1980, The Journal of endocrinology.
[270] K. Hirata,et al. Equol, adiponectin, insulin levels and risk of breast cancer. , 2013, Asian Pacific journal of cancer prevention : APJCP.
[271] Vikas Chandra,et al. Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. , 2010, Annual review of physiology.
[272] Lewis H Kuller,et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. , 2013, JAMA.
[273] Justin G Teeguarden,et al. Twenty-four hour human urine and serum profiles of bisphenol a during high-dietary exposure. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.
[274] F. Stanczyk,et al. Oral contraceptives and individual variability of circulating levels of ethinyl estradiol and progestins. , 2008, Contraception.
[275] E. Nabel. The Women's Health Initiative--a victory for women and their health. , 2013, JAMA.
[276] Justin Teeguarden,et al. Are typical human serum BPA concentrations measurable and sufficient to be estrogenic in the general population? , 2013, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[277] K. Korach,et al. Estrogenic Activity of Bisphenol A and 2,2-bis(p-Hydroxyphenyl)-1,1,1-trichloroethane (HPTE) Demonstrated in Mouse Uterine Gene Profiles , 2010, Environmental health perspectives.
[278] B. Bhavnani,et al. Transport of equine estrogens: binding of conjugated and unconjugated equine estrogens with human serum proteins. , 1985, The Journal of clinical endocrinology and metabolism.
[279] A. Duncan,et al. Isoflavones and Postmenopausal Women , 2002, Treatments in endocrinology.
[280] B. Potter,et al. Steroid sulfatase: a new target for the endocrine therapy of breast cancer. , 2007, The oncologist.
[281] J. Y. Lee,et al. Tissue distribution of estrogen receptors alpha (ER-alpha) and beta (ER-beta) mRNA in the midgestational human fetus. , 1997, The Journal of clinical endocrinology and metabolism.
[282] S. Belcher,et al. Ontogeny of rapid estrogen-mediated extracellular signal-regulated kinase signaling in the rat cerebellar cortex: potent nongenomic agonist and endocrine disrupting activity of the xenoestrogen bisphenol A. , 2005, Endocrinology.
[283] J. Alexander,et al. Bisphenol A at Environmentally Relevant Doses Inhibits Adiponectin Release from Human Adipose Tissue Explants and Adipocytes , 2008, Environmental health perspectives.
[284] M. McCarty. Isoflavones made simple - genistein's agonist activity for the beta-type estrogen receptor mediates their health benefits. , 2006, Medical hypotheses.